Location History:
- Jiangsu, CN (2015)
- Wuxi, CN (2015 - 2024)
Company Filing History:
Years Active: 2015-2025
Title: Innovations of Yongquan Chen in Metabolic Disease Treatment
Introduction
Yongquan Chen is a prominent inventor based in Wuxi, China, known for his significant contributions to the field of metabolic disease treatment. With a total of 12 patents to his name, Chen has focused on developing innovative solutions that address critical health issues such as diabetes, obesity, and cardiovascular diseases.
Latest Patents
Among his latest patents is a fusion protein that includes GIP and FGF21, which is designed for treating metabolic diseases. This invention provides a fusion protein with a general formula of R1-L-R2 or R2-L-R1, where R1 is FGF21 protein or its analogs, and R2 is GIP or its mutants. The fusion protein serves as a therapeutic agent for diseases associated with hyperglycemia and hyperlipidemia. Another notable patent is related to linoleic acid isomerase and its application in producing conjugated linoleic acid. This invention utilizes a recombinant linoleic acid isomerase to produce conjugated linoleic acids with a high conversion rate and safety, making it a valuable method in protein and microbial engineering.
Career Highlights
Yongquan Chen is affiliated with Jiangnan University, where he continues to advance his research and innovations. His work has garnered attention for its potential impact on public health, particularly in the management of metabolic disorders.
Collaborations
Chen collaborates with notable colleagues, including Hao Zhang and Haiqin Chen, contributing to a dynamic research environment that fosters innovation and development in the field.
Conclusion
Yongquan Chen's innovative work in the realm of metabolic disease treatment showcases his dedication to improving health outcomes through scientific advancements. His patents reflect a commitment to addressing some of the most pressing health challenges of our time.